4194.TWO Holy Stone Healthcare Co., Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
6.10 TWD
Close of Nov 6, 2026
5.80 10.05
Market cap
TWD 1.04B
P/E
-
P/B
8.67x
ROE
-60.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4194.TWO undervalued?

Graham number

The Graham number of Holy Stone Healthcare Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Holy Stone Healthcare Co., Ltd. fundamental analysis

No fundamental analysis for Holy Stone Healthcare Co., Ltd. yet.

Holy Stone Healthcare Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Holy Stone Healthcare Co., Ltd.

Holy Stone Healthcare Co., Ltd., together with its subsidiaries, develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis and SportVis, which are injectable medical devices for osteoarthritis and soft tissue injuries; TRUD, a medical device that contains a mixture of hyaluronic acid used for the treatment and prevention of ulcerative colitis in inflammatory bowel disease (IBD); and GAF, a gel for anal fissure healing. It also de…

Full company profile